시장보고서
상품코드
2017777

치과용 멤브레인 및 골이식 대체재 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 지역별, 부문별 예측(2026-2033년)

Dental Membrane And Bone Graft Substitutes Market Size, Share & Trends Analysis Report By Product, By Application, By Region, And Segment Forecasts, 2026 - 2033

발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 110 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ₩ 9,083,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ₩ 10,609,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ₩ 13,663,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

치과용 멤브레인 및 골이식 대체재 시장 요약

세계의 치과용 멤브레인 및 골이식 대체재 시장 규모는 2025년에 15억 8,000만 달러로 평가되었으며, 2033년까지 29억 6,000만 달러에 달할 것으로 예측되며, 2026년부터 2033년까지 CAGR 8.32%로 성장할 전망입니다.

치과용 멤브레인 및 골이식 대체재에 대한 수요는 치과 질환의 부담 증가와 심미 및 수복 치과 치료에 대한 수요 증가로 인해 증가하고 있습니다.

또한, 치과 관광의 증가도 이 산업을 견인할 것으로 예상됩니다. 치주질환, 충치, 치아 손실, 구강암을 포함한 치과 질환의 전 세계 유병률 증가는 치과용 멤브레인 및 골이식재 대체재 시장의 수요를 크게 증가시키고 있습니다. 2025년 3월에 발표된 세계보건기구(WHO) 자료에 따르면, 전 세계적으로 10억 명 이상이 심각한 치주질환을 앓고 있다고 합니다. 또한, 20세 이상 성인의 약 7%, 60세 이상 성인의 약 23%가 전치부 결손을 경험하고 있으며, 많은 경우 임플란트나 뼈 재생 시술을 필요로 합니다. 치아를 잃으면 턱뼈가 약화되는 경우가 많고, 임플란트의 성공적인 안착을 위해서는 골이식 대체재나 막이 필요하기 때문에 이러한 통계는 치과 임플란트나 뼈 재생 시술의 필요성이 높아지고 있다는 것을 보여줍니다.

또한, 구강암 발생률의 증가로 인해 치과용 골이식재에 대한 수요는 더욱 증가할 것으로 예상됩니다. 구강암의 수술적 치료에서 종양 절제 시 손상되거나 절제된 턱뼈 부위를 재건 및 복구하기 위해 뼈 이식이 자주 필요합니다. 이는 골이식 대체재가 수술의 성공과 수술 후 재활을 촉진하는 데 있어 매우 중요한 역할을 하고 있음을 보여줍니다.

자주 묻는 질문

  • 치과용 멤브레인 및 골이식 대체재 시장 규모는 어떻게 되나요?
  • 치과용 멤브레인 및 골이식 대체재에 대한 수요는 왜 증가하고 있나요?
  • 치과 관광의 증가가 치과용 멤브레인 및 골이식 대체재 시장에 미치는 영향은 무엇인가요?
  • 구강암 발생률의 증가가 치과용 골이식재 수요에 미치는 영향은 무엇인가요?
  • 치과 질환의 전 세계 유병률은 어떻게 되나요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 치과용 멤브레인 및 골이식 대체재 시장 : 변수, 동향, 범위

제4장 치과용 멤브레인 및 골이식 대체재 시장 : 제품별 추정·동향 분석

제5장 치과용 멤브레인 및 골이식 대체재 시장 : 용도별 추정·동향 분석

제6장 치과용 멤브레인 및 골이식 대체재 시장 : 지역별 추정·동향 분석

제7장 경쟁 구도

KSM 26.05.12

Dental Membrane And Bone Graft Substitutes Market Summary

The global dental membrane and bone graft substitutes market size was valued at USD 1.58 billion in 2025 and is projected to reach USD 2.96 billion by 2033, growing at a CAGR of 8.32% from 2026 to 2033. The demand for dental membranes and bone graft substitutes is rising owing to the increasing burden of dental disorders and the growing demand for aesthetic and restorative dental procedures.

In addition, increasing dental tourism is also expected to propel the industry. The rising global prevalence of dental disorders, including periodontal disease, tooth decay, tooth loss, and oral cancer, significantly drives demand in the dental membrane and bone graft substitutes market. According to World Health Organization data published in March 2025, more than 1 billion people suffer from severe periodontal disease worldwide. Additionally, about 7% of adults aged 20 and above and around 23% of those over 60 experience complete tooth loss, often requiring implants and bone regeneration procedures. These statistics underscore the growing necessity for dental implants and bone regeneration procedures, as tooth loss frequently leads to jawbone deterioration, requiring bone graft substitutes and membranes to support successful implant integration.

Moreover, the increasing incidence of oral cancer is anticipated to boost the demand for dental bone grafts further. During surgical treatment for oral cancer, bone grafts are frequently required to reconstruct and restore areas of the jawbone that have been damaged or removed during tumor excision. This underscores the vital role that bone graft substitutes play in facilitating successful surgical outcomes and post-operative rehabilitation.

Global Dental Membrane And Bone Graft Substitutes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dental membrane and bone graft substitutes market report based on product, application, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Bone Graft Substitutes (BGS)
    • Allograft
    • Demineralized Bone Matrix
    • Others
    • Autograft
    • Xenograft
    • Bovine Derived
    • Porcine Derived
    • Others
    • Synthetic
    • Hydroxyapatite (HA)
    • Tricalcium Phosphate (TCP)
    • Bioactive Glass
    • Others
  • Dental Membranes and Soft Tissue Regeneration Materials
    • Resorbable Membranes
    • Bovine -derived collagen based
    • Porcine derived collagen based
    • Others
    • Non- Resorbable Membrane
    • Expanded PTFE (ePTFE)
    • Dense PTFE (dPTFE)
    • Titanium-Reinforced PTFE
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Ridge Augmentation
  • Sinus Lift
  • Periodontal Defect Regeneration
  • Implant Bone Regeneration
  • Socket Preservation
  • Soft Tissue Regeneration
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Dental Membrane And Bone Graft Substitutes Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising burden of dental disorders
      • 3.2.1.2. Development of synthetic bone grafts
      • 3.2.1.3. Growing demand for aesthetic and restorative dental procedures
      • 3.2.1.4. Increasing dental tourism
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of dental treatments
      • 3.2.2.2. Potential risks and complications associated with dental procedures
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Increasing number of clinical trials
      • 3.2.3.2. Growing development & approvals of resorbable membranes
      • 3.2.3.3. Expansion into synthetic membrane
      • 3.2.3.4. Strategic partnerships & investment to enhance market presence
      • 3.2.3.5. Expansion opportunities in emerging economies
      • 3.2.3.6. Increasing demand for composite bone grafts
      • 3.2.3.7. Growing focus on 3D printed and custom grafts
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Regulatory and approval complexities
      • 3.2.4.2. Economic and currency exchange risks
  • 3.3. Dental Membrane And Bone Graft Substitutes Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape

Chapter 4. Dental Membrane And Bone Graft Substitutes Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Dental Membrane And Bone Graft Substitutes Market Product Movement Analysis
  • 4.3. Global Dental Membrane And Bone Graft Substitutes Market Size & Trend Analysis, by Product 2021 to 2033 (USD Million)
  • 4.4. Bone Graft Substitutes (BGS)
    • 4.4.1. Bone graft substitutes (BGS) market estimates and forecasts for 2021 to 2033 (USD Million)
      • 4.4.1.1. Allograft
        • 4.4.1.1.1. Allograft market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.1.1.1. Demineralized Bone Matrix
            • 4.4.1.1.1.1.1. Demineralized bone matrix market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.1.1.2. Others
            • 4.4.1.1.1.2.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
      • 4.4.1.2. Autograft
        • 4.4.1.2.1. Autograft market estimates and forecasts for 2021 to 2033 (USD Million)
      • 4.4.1.3. Xenograft
        • 4.4.1.3.1. Xenograft market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.3.1.1. Bovine Derived
            • 4.4.1.3.1.1.1. Bovine derived market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.3.1.2. Porcine Derived
            • 4.4.1.3.1.2.1. Porcine derived market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.3.1.3. Others
            • 4.4.1.3.1.3.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
      • 4.4.1.4. Synthetic
        • 4.4.1.4.1. Synthetic market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.4.1.1. Hydroxyapatite (HA)
            • 4.4.1.4.1.1.1. Hydroxyapatite (HA) market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.4.1.2. Tricalcium Phosphate (TCP)
            • 4.4.1.4.1.2.1. Tricalcium phosphate (TCP) market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.4.1.3. Bioactive Glass
            • 4.4.1.4.1.3.1. Bioactive glass market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.4.1.4.1.4. Others
            • 4.4.1.4.1.4.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.5. Dental Membranes and Soft Tissue Regeneration Materials
    • 4.5.1. Dental membranes and soft tissue regeneration materials market estimates and forecasts for 2021 to 2033 (USD Million)
      • 4.5.1.1. Resorbable membranes
        • 4.5.1.1.1. Resorbable membranes market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.5.1.1.1.1. Bovine -derived collagen based
            • 4.5.1.1.1.1.1. Bovine -derived collagen based market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.5.1.1.1.2. Porcine derived collagen based
            • 4.5.1.1.1.2.1. Porcine derived collagen based market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.5.1.1.1.3. Others
            • 4.5.1.1.1.3.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
      • 4.5.1.2. Non resorbable membranes
        • 4.5.1.2.1. Non resorbable membranes market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.5.1.2.1.1. Expanded PTFE (ePTFE)
            • 4.5.1.2.1.1.1. Expanded PTFE (ePTFE) market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.5.1.2.1.2. Dense PTFE (dPTFE)
            • 4.5.1.2.1.2.1. Dense PTFE (dPTFE) market estimates and forecasts for 2021 to 2033 (USD Million)
          • 4.5.1.2.1.3. Titanium-Reinforced PTFE
            • 4.5.1.2.1.3.1. Titanium-reinforced PTFE market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 5. Dental Membrane And Bone Graft Substitutes Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Dental Membrane And Bone Graft Substitutes Market Application Movement Analysis
  • 5.3. Global Dental Membrane And Bone Graft Substitutes Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Ridge Augmentation
    • 5.4.1. Ridge augmentation market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5. Sinus Lift
    • 5.5.1. Sinus lift market estimates and forecast 2021 to 2033 (USD Million)
  • 5.6. Periodontal Defect Regeneration
    • 5.6.1. Periodontal defect regeneration market estimates and forecast 2021 to 2033 (USD Million)
  • 5.7. Implant Bone Regeneration
    • 5.7.1. Implant bone regeneration market estimates and forecast 2021 to 2033 (USD Million)
  • 5.8. Socket Preservation
    • 5.8.1. Socket preservation market estimates and forecasts for 2021 to 2033 (USD Million)
  • 5.9. Soft Tissue Regeneration
    • 5.9.1. Soft tissue regeneration market estimates and forecast 2021 to 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Dental Membrane And Bone Graft Substitutes Market: Regional Estimates & Trend Analysis By Product and By Application

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 6.3. North America
    • 6.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Competitive scenario
      • 6.3.2.3. Regulatory framework
      • 6.3.2.4. Reimbursement scenario
      • 6.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Competitive scenario
      • 6.3.3.3. Regulatory framework
      • 6.3.3.4. Reimbursement scenario
      • 6.3.3.5. Canada market estimates and forecasts, 2021 - 2033
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Competitive scenario
      • 6.3.4.3. Regulatory framework
      • 6.3.4.4. Reimbursement scenario
      • 6.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Competitive scenario
      • 6.4.1.3. Regulatory framework
      • 6.4.1.4. Reimbursement scenario
      • 6.4.1.5. UK market estimates and forecasts, 2021 - 2033
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Competitive scenario
      • 6.4.2.3. Regulatory framework
      • 6.4.2.4. Reimbursement scenario
      • 6.4.2.5. Germany market estimates and forecasts, 2021 - 2033
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Competitive scenario
      • 6.4.3.3. Regulatory framework
      • 6.4.3.4. Reimbursement scenario
      • 6.4.3.5. France market estimates and forecasts, 2021 - 2033
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Competitive scenario
      • 6.4.4.3. Regulatory framework
      • 6.4.4.4. Reimbursement scenario
      • 6.4.4.5. Italy market estimates and forecasts, 2021 - 2033
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Competitive scenario
      • 6.4.5.3. Regulatory framework
      • 6.4.5.4. Reimbursement scenario
      • 6.4.5.5. Spain market estimates and forecasts, 2021 - 2033
    • 6.4.6. Denmark
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Competitive scenario
      • 6.4.6.3. Regulatory framework
      • 6.4.6.4. Reimbursement scenario
      • 6.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Competitive scenario
      • 6.4.7.3. Regulatory framework
      • 6.4.7.4. Reimbursement scenario
      • 6.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
    • 6.4.8. Norway
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Competitive scenario
      • 6.4.8.3. Regulatory framework
      • 6.4.8.4. Reimbursement scenario
      • 6.4.8.5. Norway market estimates and forecasts, 2021 - 2033
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Competitive scenario
      • 6.5.1.3. Regulatory framework
      • 6.5.1.4. Reimbursement scenario
      • 6.5.1.5. Japan market estimates and forecasts, 2021 - 2033
    • 6.5.2. India
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Reimbursement scenario
      • 6.5.2.5. India market estimates and forecasts, 2021 - 2033
    • 6.5.3. China
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework
      • 6.5.3.4. Reimbursement scenario
      • 6.5.3.5. China market estimates and forecasts, 2021 - 2033
    • 6.5.4. South Korea
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Competitive scenario
      • 6.5.4.3. Regulatory framework
      • 6.5.4.4. Reimbursement scenario
      • 6.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Competitive scenario
      • 6.5.5.3. Regulatory framework
      • 6.5.5.4. Reimbursement scenario
      • 6.5.5.5. Australia market estimates and forecasts, 2021 - 2033
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Competitive scenario
      • 6.5.6.3. Regulatory framework
      • 6.5.6.4. Reimbursement scenario
      • 6.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Competitive scenario
      • 6.6.1.3. Regulatory framework
      • 6.6.1.4. Reimbursement scenario
      • 6.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Reimbursement scenario
      • 6.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Competitive scenario
      • 6.7.1.3. Regulatory framework
      • 6.7.1.4. Reimbursement scenario
      • 6.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. Reimbursement scenario
      • 6.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Reimbursement scenario
      • 6.7.3.5. UAE market estimates and forecasts, 2021 - 2033
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. Reimbursement scenario
      • 6.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Innovators
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Global Key company market share analysis, 2025
    • 7.3.4. Dentsply Sirona
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Bioteck S.p.A.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Maxigen Biotech Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Institut Straumann AG
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Nobel Biocare Services AG (Envista)
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Geistlich Holding
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. ZimVie Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. NovaBone (Halma)
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Osteogenics Biomedical (Envista)
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Regenity
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Medtronic
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. BioHorizons
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. REGEDENT AG
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives
    • 7.3.17. IDL Dental Technologies LTD
      • 7.3.17.1. Company overview
      • 7.3.17.2. Financial performance
      • 7.3.17.3. Product benchmarking
      • 7.3.17.4. Strategic initiatives
    • 7.3.18. EUCARE PHARMACEUTICALS (P) LTD
      • 7.3.18.1. Company overview
      • 7.3.18.2. Financial performance
      • 7.3.18.3. Product benchmarking
      • 7.3.18.4. Strategic initiatives
    • 7.3.19. Curasan, Inc.
      • 7.3.19.1. Company overview
      • 7.3.19.2. Financial performance
      • 7.3.19.3. Product benchmarking
      • 7.3.19.4. Strategic initiatives
    • 7.3.20. TBR Dental
      • 7.3.20.1. Company overview
      • 7.3.20.2. Financial performance
      • 7.3.20.3. Product benchmarking
      • 7.3.20.4. Strategic initiatives
    • 7.3.21. DentiumUSA
      • 7.3.21.1. Company overview
      • 7.3.21.2. Financial performance
      • 7.3.21.3. Product benchmarking
      • 7.3.21.4. Strategic initiatives
    • 7.3.22. Tecnoss Dental Srl (Tecnoss s.r.l.)
      • 7.3.22.1. Company overview
      • 7.3.22.2. Financial performance
      • 7.3.22.3. Product benchmarking
      • 7.3.22.4. Strategic initiatives
    • 7.3.23. Unicare Biomedical, Inc.
      • 7.3.23.1. Company overview
      • 7.3.23.2. Financial performance
      • 7.3.23.3. Product benchmarking
      • 7.3.23.4. Strategic initiatives
    • 7.3.24. Neoss
      • 7.3.24.1. Company overview
      • 7.3.24.2. Financial performance
      • 7.3.24.3. Product benchmarking
      • 7.3.24.4. Strategic initiatives
    • 7.3.25. Advanced Medical Solutions Group plc
      • 7.3.25.1. Company overview
      • 7.3.25.2. Financial performance
      • 7.3.25.3. Product benchmarking
      • 7.3.25.4. Strategic initiatives
    • 7.3.26. B&B Dental Implant Company
      • 7.3.26.1. Company overview
      • 7.3.26.2. Financial performance
      • 7.3.26.3. Product benchmarking
      • 7.3.26.4. Strategic initiatives
    • 7.3.27. Botiss
      • 7.3.27.1. Company overview
      • 7.3.27.2. Financial performance
      • 7.3.27.3. Product benchmarking
      • 7.3.27.4. Strategic initiatives
    • 7.3.28. Septodont Holding
      • 7.3.28.1. Company overview
      • 7.3.28.2. Financial performance
      • 7.3.28.3. Product benchmarking
      • 7.3.28.4. Strategic initiatives
    • 7.3.29. Implant Direct Corporation (Envista)
      • 7.3.29.1. Company overview
      • 7.3.29.2. Financial performance
      • 7.3.29.3. Product benchmarking
      • 7.3.29.4. Strategic initiatives
    • 7.3.30. META BIOMED CO,. LTD
      • 7.3.30.1. Company overview
      • 7.3.30.2. Financial performance
      • 7.3.30.3. Product benchmarking
      • 7.3.30.4. Strategic initiatives
    • 7.3.31. SigmaGraft Biomaterials
      • 7.3.31.1. Company overview
      • 7.3.31.2. Financial performance
      • 7.3.31.3. Product benchmarking
      • 7.3.31.4. Strategic initiatives
  • 7.4. Heat Map Analysis/ Company Market Position Analysis
  • 7.5. Estimated Company Market Share Analysis, 2024
  • 7.6. List of Other Key Market Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기